Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 3/20 | 0.50 |
| ▸ | DRD3 | P35462 | 2/20 | 0.50 |
| ▸ | DRD1 | P21728 | 2/20 | 0.50 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.50 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.50 |
| ▸ | DRD4 | P21917 | 1/20 | 0.50 |
| ▸ | DRD5 | P21918 | 1/20 | 0.50 |
| ▸ | HSD17B1 | P14061 | 7/20 | 0.49 |
| ▸ | HSD17B2 | P37059 | 7/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.46 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9416589 | 0.90 | ENPP2 (0.54) | DRD2DRD3DRD1DRD4DRD5 | |
| SCHEMBL9416563 | 0.83 | HSD17B1 (0.51) | DRD2DRD3DRD1DRD4DRD5 | |
| SCHEMBL19686193 | 0.82 | DRD2 (0.56) | DRD2DRD3DRD1DRD4DRD5 | |
| SCHEMBL31126663 | 0.82 | ALDH1A1 (0.54) | DRD2DRD3DRD1DRD4DRD5 | |
| SCHEMBL31126662 | 0.82 | ALDH1A1 (0.54) | DRD2DRD3DRD1DRD4DRD5 | |
| SCHEMBL234552 | 0.82 | ALDH1A1 (0.54) | DRD2DRD3DRD1DRD4DRD5 | |
| Bromide SCHEMBL21056120 | 0.81 | DRD2 (0.54) | DRD2DRD3DRD1DRD4DRD5 | |
| SCHEMBL21674318 | 0.81 | S1PR1 (0.54) | CHRNB2CHRNA4ENPP2 | |
| SCHEMBL19049389 | 0.80 | CARM1 (0.62) | DRD2DRD3DRD1DRD4DRD5 | |
| SCHEMBL19291460 | 0.80 | CHRNB2 (0.53) | CHRNB2CHRNA4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021148805-A1 | TOPICAL PHARMACEUTICAL COMPOSITIONS COMPRISING IMIDAZO[1,2-B]PYRIDAZINE COMPOUNDS | BENEVOLENTAI BIO LIMITED (GB) | 2021-07-29 | — | — | WO | disclosed |
| WO-2020039209-A1 | IMIDAZO[1,2-B]PYRIDAZINES AS TRK INHIBITORS | BENEVOLENTAI BIO LIMITED (GB) | 2020-02-27 | — | — | WO | disclosed |
| EP-2054373-B1 | IMPROVED PROCESS FOR THE PREPARATION OF RIVASTIGMINE | ALEMBIC LTD (IN) | 2010-06-30 | — | — | EP | disclosed |
| US-7683205-B2 | Process for the preparation of Rivastigmine | ALEMBIC LIMITED (IN) | 2010-03-23 | — | — | US | disclosed |
| EP-2054373-A1 | IMPROVED PROCESS FOR THE PREPARATION OF RIVASTIGMINE | Alembic Limited (IN) | 2009-05-06 | — | — | EP | disclosed |
| WO-2008020452-A1 | IMPROVED PROCESS FOR THE PREPARATION OF RIVASTIGMINE | ALEMBIC LIMITED (IN) | 2008-02-21 | — | — | WO | disclosed |
| US-20080045743-A1 | Process for the preparation of Rivastigmine | ALEMBIC LIMITED (IN) | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045743-A1 | Process for the preparation of Rivastigmine | HNMT, HRH3, SUV39H2 | DRD2 322/4885DRD3 266/4885DRD1 359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.